![Ulf Grawunder](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ulf Grawunder
Director/Board Member at
WUXI XDC CAYMAN INC.
Net worth: 75 000 $ as of 31/07/2026
Profile
Ulf Grawunder was the founder of 4-Antibody AG, founded in 2002, where the title held was Chief Scientist from 2009 to 2010.
Dr. Grawunder was the founder of NBE-Therapeutics AG, founded in 2012, with the title Chief Executive Officer & Director from 2012 to 2020.
Dr. Grawunder is the founder of T-CURX GmbH, founded in 2017, currently holding the title Chief Executive Officer.
Current jobs include Independent Non-Executive Director at BioDlink International Co., Ltd. starting in 2026, Independent Director at Adagene, Inc. starting in 2024, Independent Non-Executive Director at WuXi XDC Cayman, Inc. starting in 2023, and Managing Partner at Viopas Venture Consulting GmbH starting in 2022.
Former job includes Principal at the University of Southern California.
Education includes a doctorate from the University of Basel conferred in 1994 and a graduate degree from the University of Bayreuth conferred in 1991.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ADAGENE, INC. 0.05% | 13/08/2026 | 25,000 ( 0.05% ) | 75 000 $ | 31/07/2026 |
Ulf Grawunder active positions
| Companies | Position | Start |
|---|---|---|
| WUXI XDC CAYMAN INC. | Director/Board Member | 01/11/2023 |
| ADAGENE INC. | Director/Board Member | 01/04/2024 |
| BIODLINK INTERNATIONAL COMPANY LIMITED | Director/Board Member | 29/04/2026 |
T-CURX GmbH
 T-CURX GmbH BiotechnologyHealth Technology Operates as a biotech company that develops immunotherapies to treat cancer | Chief Executive Officer | 06/03/2017 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting invests in companies located in Europe, primarily in Switzerland, Austria, and Germany. The firm focused on healthcare sectors includes digital health & medtech, pharma and biotech. It provides financing for pre-seed, early and late-stage capital requirements. | Corporate Officer/Principal | 01/01/2022 |
Former positions of Ulf Grawunder
| Companies | Position | End |
|---|---|---|
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
NBE-Therapeutics AG
 NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Chief Executive Officer | 03/08/2020 |
4-Antibody AG
 4-Antibody AG Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Founder | - |
Training of Ulf Grawunder
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
68
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
University of Southern California
University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
4-Antibody AG
4-Antibody AG Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Health Technology |
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Bayreuth
 University of Bayreuth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TOT BIOPHARM International Co. Ltd.
 TOT BIOPHARM International Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets anti-tumor drugs | Health Technology |
Adagene, Inc.
 Adagene, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which discovers and develops novel antibody-based cancer immunotherapies | Health Technology |
NBE-Therapeutics AG
NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Health Technology |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting invests in companies located in Europe, primarily in Switzerland, Austria, and Germany. The firm focused on healthcare sectors includes digital health & medtech, pharma and biotech. It provides financing for pre-seed, early and late-stage capital requirements. | Finance |
WuXi XDC Cayman, Inc.
 WuXi XDC Cayman, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a holding company that provides contract, research, development and manufacturing services | Commercial Services |
T-CURX GmbH
T-CURX GmbH BiotechnologyHealth Technology Operates as a biotech company that develops immunotherapies to treat cancer | Health Technology |
- Stock Market
- Insiders
- Ulf Grawunder
